You'll never Guess What's in the Covid Test & mRNA Gene Therapy
- Thread starter EGO-TRIP
- Start date
I tried to bring this issue before and they deleted my page.This is a very important issue that Nobody should get involve in this in no way shape or form.Very serious consequences to be had for those who do get involve.
Good info bruh!!
But as usual, only a small percent will use critical thinking on this topic!! The other 85% will sit in-front of their television and gobble up whatever the talking heads on tv, the media/social media platforms or so-called leaders or billionaires tell them!!!
I know right..............But this is such a serious matter,it's more serious than what people think it is.there are dire ,serious and severe consequences to be had as a result for somebody getting themselves involved in this matter.Ive been trying to stressed this shit hard to bone to people.Do not take a Covid test.
I wish y’all would take even 5 minutes to research the nutcases whom you quote.
Ok...............please explain.
Oh look it's a circle jerk of the local bgol conspiracy retards.
OMG this is the dumbest shit I have ever seen
Well ummm ummmm how do you explain this then.?This is coming directly from the horses mouth and not his ass.Coming straight from yours truely John Hopkins University.
OMG this is the dumbest shit I have ever seen
Johns Hopkins Researchers Engineer Tiny, Shape-Changing Machines That Deliver Medicine Efficiently to the GI Tract
“Theragrippers” are inspired by a parasitic worm that clamps onto its host’s intestines
Johns Hopkins Researchers Engineer Tiny, Shape-Changing Machines That Deliver Medicine Efficiently to the GI Tract
11/03/2020
“Theragrippers” are inspired by a parasitic worm that clamps onto its host’s intestines
When an open theragripper, left, is exposed to internal body temperatures, it closes on the intestinal wall. In the gripper’s center is a space for a small dose of a drug. Credit: Johns Hopkins University
Inspired by a parasitic worm that digs its sharp teeth into its host’s intestines, Johns Hopkins researchers have designed tiny, star-shaped microdevices that can latch onto intestinal mucosa and release drugs into the body.
David Gracias, Ph.D., a professor in the Johns Hopkins University Whiting School of Engineering, and Johns Hopkins gastroenterologist Florin M. Selaru, M.D., director of the Johns Hopkins Inflammatory Bowel Disease Center, led a team of researchers and biomedical engineers that designed and tested shape-changing microdevices that mimic the way the parasitic hookworm affixes itself to an organism’s intestines.
| A theragripper is about the size of a speck of dust. This swab contains dozens of the tiny devices. Credit: Johns Hopkins University. |
Made of metal and thin, shape-changing film and coated in a heat-sensitive paraffin wax, “theragrippers,” each roughly the size of a dust speck, potentially can carry any drug and release it gradually into the body.
The team published results of an animal study this week as the cover article in the journal Science Advances.
Gradual or extended release of a drug is a long-sought goal in medicine. Selaru explains that a problem with extended-release drugs is they often make their way entirely through the gastrointestinal tract before they’ve finished dispensing their medication.
“Normal constriction and relaxation of GI tract muscles make it impossible for extended-release drugs to stay in the intestine long enough for the patient to receive the full dose,” says Selaru, who has collaborated with Gracias for more than 10 years. “We’ve been working to solve this problem by designing these small drug carriers that can autonomously latch onto the intestinal mucosa and keep the drug load inside the GI tract for a desired duration of time.”
Thousands of theragrippers can be deployed in the GI tract. When the paraffin wax coating on the grippers reaches the temperature inside the body, the devices close autonomously and clamp onto the colonic wall. The closing action causes the tiny, six-pointed devices to dig into the mucosa and remain attached to the colon, where they are retained and release their medicine payloads gradually into the body. Eventually, the theragrippers lose their hold on the tissue and are cleared from the intestine via normal gastrointestinal muscular function.
Gracias notes advances in the field of biomedical engineering in recent years.
“We have seen the introduction of dynamic, microfabricated smart devices that can be controlled by electrical or chemical signals,” he says. “But these grippers are so small that batteries, antennas and other components will not fit on them.”
Theragrippers, says Gracias, don’t rely on electricity, wireless signals or external controls. “Instead, they operate like small, compressed springs with a temperature-triggered coating on the devices that releases the stored energy autonomously at body temperature.”
The Johns Hopkins researchers fabricated the devices with about 6,000 theragrippers per 3-inch silicon wafer. In their animal experiments, they loaded a pain-relieving drug onto the grippers. The researchers’ studies found that the animals into which theragrippers were administered had higher concentrates of the pain reliever in their bloodstreams than did the control group. The drug stayed in the test subjects’ systems for nearly 12 hours versus two hours in the control group.
In addition to Gracias and Selaru, the journal article’s authors are Arijit Ghosh, Liyi Xu, Neha Gupta, Qianru Lin, Gayatri Pahapale, Wangqu Lu and Anjishnu Sarkar of the Johns Hopkins University Department of Chemical and Biomolecular Engineering; Ling Li and Venkata Akshintala of the Johns Hopkins University School of Medicine’s Division of Gastroenterology and Hepatology; Ranjeet Dash, Jenny Lam and Rana Rais of Johns Hopkins Drug Discovery and the Johns Hopkins University School of Medicine Department of Neurology.
The work was funded by the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health and the National Science Foundation. The Johns Hopkins University has filed patents on behalf of Gracias and Selaru related to this technology in accordance with the university’s conflict of interest policies.
Johns Hopkins Researchers Engineer Tiny, Shape-Changing Machines That Deliver Medicine Efficiently to the GI Tract
11/03/2020
“Theragrippers” are inspired by a parasitic worm that clamps onto its host’s intestines
When an open theragripper, left, is exposed to internal body temperatures, it closes on the intestinal wall. In the gripper’s center is a space for a small dose of a drug. Credit: Johns Hopkins University
Inspired by a parasitic worm that digs its sharp teeth into its host’s intestines, Johns Hopkins researchers have designed tiny, star-shaped microdevices that can latch onto intestinal mucosa and release drugs into the body.
David Gracias, Ph.D., a professor in the Johns Hopkins University Whiting School of Engineering, and Johns Hopkins gastroenterologist Florin M. Selaru, M.D., director of the Johns Hopkins Inflammatory Bowel Disease Center, led a team of researchers and biomedical engineers that designed and tested shape-changing microdevices that mimic the way the parasitic hookworm affixes itself to an organism’s intestines.
| A theragripper is about the size of a speck of dust. This swab contains dozens of the tiny devices. Credit: Johns Hopkins University. |
Made of metal and thin, shape-changing film and coated in a heat-sensitive paraffin wax, “theragrippers,” each roughly the size of a dust speck, potentially can carry any drug and release it gradually into the body.
The team published results of an animal study this week as the cover article in the journal Science Advances.
Gradual or extended release of a drug is a long-sought goal in medicine. Selaru explains that a problem with extended-release drugs is they often make their way entirely through the gastrointestinal tract before they’ve finished dispensing their medication.
“Normal constriction and relaxation of GI tract muscles make it impossible for extended-release drugs to stay in the intestine long enough for the patient to receive the full dose,” says Selaru, who has collaborated with Gracias for more than 10 years. “We’ve been working to solve this problem by designing these small drug carriers that can autonomously latch onto the intestinal mucosa and keep the drug load inside the GI tract for a desired duration of time.”
Thousands of theragrippers can be deployed in the GI tract. When the paraffin wax coating on the grippers reaches the temperature inside the body, the devices close autonomously and clamp onto the colonic wall. The closing action causes the tiny, six-pointed devices to dig into the mucosa and remain attached to the colon, where they are retained and release their medicine payloads gradually into the body. Eventually, the theragrippers lose their hold on the tissue and are cleared from the intestine via normal gastrointestinal muscular function.
Gracias notes advances in the field of biomedical engineering in recent years.
“We have seen the introduction of dynamic, microfabricated smart devices that can be controlled by electrical or chemical signals,” he says. “But these grippers are so small that batteries, antennas and other components will not fit on them.”
Theragrippers, says Gracias, don’t rely on electricity, wireless signals or external controls. “Instead, they operate like small, compressed springs with a temperature-triggered coating on the devices that releases the stored energy autonomously at body temperature.”
The Johns Hopkins researchers fabricated the devices with about 6,000 theragrippers per 3-inch silicon wafer. In their animal experiments, they loaded a pain-relieving drug onto the grippers. The researchers’ studies found that the animals into which theragrippers were administered had higher concentrates of the pain reliever in their bloodstreams than did the control group. The drug stayed in the test subjects’ systems for nearly 12 hours versus two hours in the control group.
In addition to Gracias and Selaru, the journal article’s authors are Arijit Ghosh, Liyi Xu, Neha Gupta, Qianru Lin, Gayatri Pahapale, Wangqu Lu and Anjishnu Sarkar of the Johns Hopkins University Department of Chemical and Biomolecular Engineering; Ling Li and Venkata Akshintala of the Johns Hopkins University School of Medicine’s Division of Gastroenterology and Hepatology; Ranjeet Dash, Jenny Lam and Rana Rais of Johns Hopkins Drug Discovery and the Johns Hopkins University School of Medicine Department of Neurology.
The work was funded by the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health and the National Science Foundation. The Johns Hopkins University has filed patents on behalf of Gracias and Selaru related to this technology in accordance with the university’s conflict of interest policies.
The technology is available for licensing through Johns Hopkins Technology Ventures.
Official link:https://www.hopkinsmedicine.org/new...-deliver-medicine-efficiently-to-the-gi-tract
Disclaimer:I wanna see how your Brilliant genius ass is gonna explain that.What is your clapback gonna be in regards to that.?Coming straight and direct from John Hopkins University Baltimore,Maryland
Well homie explain this then.I wanna see how you gonna justify this.This is coming directly from John Hopkins University Baltimore,Maryland.So you can see it for yourself.I will provide the direct link coming from John Hopkins University for you to read.So in retrospect if you took the the Covid19 PCR Test you have already been vaccinated you just didnt know it.
Johns Hopkins Researchers Engineer Tiny, Shape-Changing Machines That Deliver Medicine Efficiently to the GI Tract
“Theragrippers” are inspired by a parasitic worm that clamps onto its host’s intestines
Johns Hopkins Researchers Engineer Tiny, Shape-Changing Machines That Deliver Medicine Efficiently to the GI Tract
11/03/2020
“Theragrippers” are inspired by a parasitic worm that clamps onto its host’s intestines
When an open theragripper, left, is exposed to internal body temperatures, it closes on the intestinal wall. In the gripper’s center is a space for a small dose of a drug. Credit: Johns Hopkins University
Inspired by a parasitic worm that digs its sharp teeth into its host’s intestines, Johns Hopkins researchers have designed tiny, star-shaped microdevices that can latch onto intestinal mucosa and release drugs into the body.
David Gracias, Ph.D., a professor in the Johns Hopkins University Whiting School of Engineering, and Johns Hopkins gastroenterologist Florin M. Selaru, M.D., director of the Johns Hopkins Inflammatory Bowel Disease Center, led a team of researchers and biomedical engineers that designed and tested shape-changing microdevices that mimic the way the parasitic hookworm affixes itself to an organism’s intestines.
| A theragripper is about the size of a speck of dust. This swab contains dozens of the tiny devices. Credit: Johns Hopkins University. |
The team published results of an animal study this week as the cover article in the journal Science Advances.
Gradual or extended release of a drug is a long-sought goal in medicine. Selaru explains that a problem with extended-release drugs is they often make their way entirely through the gastrointestinal tract before they’ve finished dispensing their medication.
“Normal constriction and relaxation of GI tract muscles make it impossible for extended-release drugs to stay in the intestine long enough for the patient to receive the full dose,” says Selaru, who has collaborated with Gracias for more than 10 years. “We’ve been working to solve this problem by designing these small drug carriers that can autonomously latch onto the intestinal mucosa and keep the drug load inside the GI tract for a desired duration of time.”
Thousands of theragrippers can be deployed in the GI tract. When the paraffin wax coating on the grippers reaches the temperature inside the body, the devices close autonomously and clamp onto the colonic wall. The closing action causes the tiny, six-pointed devices to dig into the mucosa and remain attached to the colon, where they are retained and release their medicine payloads gradually into the body. Eventually, the theragrippers lose their hold on the tissue and are cleared from the intestine via normal gastrointestinal muscular function.
Gracias notes advances in the field of biomedical engineering in recent years.
“We have seen the introduction of dynamic, microfabricated smart devices that can be controlled by electrical or chemical signals,” he says. “But these grippers are so small that batteries, antennas and other components will not fit on them.”
Theragrippers, says Gracias, don’t rely on electricity, wireless signals or external controls. “Instead, they operate like small, compressed springs with a temperature-triggered coating on the devices that releases the stored energy autonomously at body temperature.”
The Johns Hopkins researchers fabricated the devices with about 6,000 theragrippers per 3-inch silicon wafer. In their animal experiments, they loaded a pain-relieving drug onto the grippers. The researchers’ studies found that the animals into which theragrippers were administered had higher concentrates of the pain reliever in their bloodstreams than did the control group. The drug stayed in the test subjects’ systems for nearly 12 hours versus two hours in the control group.
In addition to Gracias and Selaru, the journal article’s authors are Arijit Ghosh, Liyi Xu, Neha Gupta, Qianru Lin, Gayatri Pahapale, Wangqu Lu and Anjishnu Sarkar of the Johns Hopkins University Department of Chemical and Biomolecular Engineering; Ling Li and Venkata Akshintala of the Johns Hopkins University School of Medicine’s Division of Gastroenterology and Hepatology; Ranjeet Dash, Jenny Lam and Rana Rais of Johns Hopkins Drug Discovery and the Johns Hopkins University School of Medicine Department of Neurology.
The work was funded by the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health and the National Science Foundation. The Johns Hopkins University has filed patents on behalf of Gracias and Selaru related to this technology in accordance with the university’s conflict of interest policies.
Johns Hopkins Researchers Engineer Tiny, Shape-Changing Machines That Deliver Medicine Efficiently to the GI Tract
11/03/2020
“Theragrippers” are inspired by a parasitic worm that clamps onto its host’s intestines
When an open theragripper, left, is exposed to internal body temperatures, it closes on the intestinal wall. In the gripper’s center is a space for a small dose of a drug. Credit: Johns Hopkins University
Inspired by a parasitic worm that digs its sharp teeth into its host’s intestines, Johns Hopkins researchers have designed tiny, star-shaped microdevices that can latch onto intestinal mucosa and release drugs into the body.
David Gracias, Ph.D., a professor in the Johns Hopkins University Whiting School of Engineering, and Johns Hopkins gastroenterologist Florin M. Selaru, M.D., director of the Johns Hopkins Inflammatory Bowel Disease Center, led a team of researchers and biomedical engineers that designed and tested shape-changing microdevices that mimic the way the parasitic hookworm affixes itself to an organism’s intestines.
| A theragripper is about the size of a speck of dust. This swab contains dozens of the tiny devices. Credit: Johns Hopkins University. |
The team published results of an animal study this week as the cover article in the journal Science Advances.
Gradual or extended release of a drug is a long-sought goal in medicine. Selaru explains that a problem with extended-release drugs is they often make their way entirely through the gastrointestinal tract before they’ve finished dispensing their medication.
“Normal constriction and relaxation of GI tract muscles make it impossible for extended-release drugs to stay in the intestine long enough for the patient to receive the full dose,” says Selaru, who has collaborated with Gracias for more than 10 years. “We’ve been working to solve this problem by designing these small drug carriers that can autonomously latch onto the intestinal mucosa and keep the drug load inside the GI tract for a desired duration of time.”
Thousands of theragrippers can be deployed in the GI tract. When the paraffin wax coating on the grippers reaches the temperature inside the body, the devices close autonomously and clamp onto the colonic wall. The closing action causes the tiny, six-pointed devices to dig into the mucosa and remain attached to the colon, where they are retained and release their medicine payloads gradually into the body. Eventually, the theragrippers lose their hold on the tissue and are cleared from the intestine via normal gastrointestinal muscular function.
Gracias notes advances in the field of biomedical engineering in recent years.
“We have seen the introduction of dynamic, microfabricated smart devices that can be controlled by electrical or chemical signals,” he says. “But these grippers are so small that batteries, antennas and other components will not fit on them.”
Theragrippers, says Gracias, don’t rely on electricity, wireless signals or external controls. “Instead, they operate like small, compressed springs with a temperature-triggered coating on the devices that releases the stored energy autonomously at body temperature.”
The Johns Hopkins researchers fabricated the devices with about 6,000 theragrippers per 3-inch silicon wafer. In their animal experiments, they loaded a pain-relieving drug onto the grippers. The researchers’ studies found that the animals into which theragrippers were administered had higher concentrates of the pain reliever in their bloodstreams than did the control group. The drug stayed in the test subjects’ systems for nearly 12 hours versus two hours in the control group.
In addition to Gracias and Selaru, the journal article’s authors are Arijit Ghosh, Liyi Xu, Neha Gupta, Qianru Lin, Gayatri Pahapale, Wangqu Lu and Anjishnu Sarkar of the Johns Hopkins University Department of Chemical and Biomolecular Engineering; Ling Li and Venkata Akshintala of the Johns Hopkins University School of Medicine’s Division of Gastroenterology and Hepatology; Ranjeet Dash, Jenny Lam and Rana Rais of Johns Hopkins Drug Discovery and the Johns Hopkins University School of Medicine Department of Neurology.
The work was funded by the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health and the National Science Foundation. The Johns Hopkins University has filed patents on behalf of Gracias and Selaru related to this technology in accordance with the university’s conflict of interest policies.
The technology is available for licensing through Johns Hopkins Technology Ventures.
Official link:https://www.hopkinsmedicine.org/new...-deliver-medicine-efficiently-to-the-gi-tract
Disclaimer:I wanna see how your Brilliant genius ass is gonna explain that.What is your clapback gonna be in regards to that.?Coming straight and direct from John Hopkins University Baltimore,Maryland
Where, you blockhead, immensely retarded muhfucka, is ANY reputable source proving that theragrippers are on COVID testing swabs?Well ummm ummmm how do you explain this then.?This is coming directly from the horses mouth and not his ass.Coming straight from yours truely John Hopkins University.
Johns Hopkins Researchers Engineer Tiny, Shape-Changing Machines That Deliver Medicine Efficiently to the GI Tract
“Theragrippers” are inspired by a parasitic worm that clamps onto its host’s intestines
Johns Hopkins Researchers Engineer Tiny, Shape-Changing Machines That Deliver Medicine Efficiently to the GI Tract
11/03/2020
“Theragrippers” are inspired by a parasitic worm that clamps onto its host’s intestines
When an open theragripper, left, is exposed to internal body temperatures, it closes on the intestinal wall. In the gripper’s center is a space for a small dose of a drug. Credit: Johns Hopkins University
Inspired by a parasitic worm that digs its sharp teeth into its host’s intestines, Johns Hopkins researchers have designed tiny, star-shaped microdevices that can latch onto intestinal mucosa and release drugs into the body.
David Gracias, Ph.D., a professor in the Johns Hopkins University Whiting School of Engineering, and Johns Hopkins gastroenterologist Florin M. Selaru, M.D., director of the Johns Hopkins Inflammatory Bowel Disease Center, led a team of researchers and biomedical engineers that designed and tested shape-changing microdevices that mimic the way the parasitic hookworm affixes itself to an organism’s intestines.
Made of metal and thin, shape-changing film and coated in a heat-sensitive paraffin wax, “theragrippers,” each roughly the size of a dust speck, potentially can carry any drug and release it gradually into the body.
A theragripper is about the size of a speck of dust. This swab contains dozens of the tiny devices. Credit: Johns Hopkins University.
The team published results of an animal study this week as the cover article in the journal Science Advances.
Gradual or extended release of a drug is a long-sought goal in medicine. Selaru explains that a problem with extended-release drugs is they often make their way entirely through the gastrointestinal tract before they’ve finished dispensing their medication.
“Normal constriction and relaxation of GI tract muscles make it impossible for extended-release drugs to stay in the intestine long enough for the patient to receive the full dose,” says Selaru, who has collaborated with Gracias for more than 10 years. “We’ve been working to solve this problem by designing these small drug carriers that can autonomously latch onto the intestinal mucosa and keep the drug load inside the GI tract for a desired duration of time.”
Thousands of theragrippers can be deployed in the GI tract. When the paraffin wax coating on the grippers reaches the temperature inside the body, the devices close autonomously and clamp onto the colonic wall. The closing action causes the tiny, six-pointed devices to dig into the mucosa and remain attached to the colon, where they are retained and release their medicine payloads gradually into the body. Eventually, the theragrippers lose their hold on the tissue and are cleared from the intestine via normal gastrointestinal muscular function.
Gracias notes advances in the field of biomedical engineering in recent years.
“We have seen the introduction of dynamic, microfabricated smart devices that can be controlled by electrical or chemical signals,” he says. “But these grippers are so small that batteries, antennas and other components will not fit on them.”
Theragrippers, says Gracias, don’t rely on electricity, wireless signals or external controls. “Instead, they operate like small, compressed springs with a temperature-triggered coating on the devices that releases the stored energy autonomously at body temperature.”
The Johns Hopkins researchers fabricated the devices with about 6,000 theragrippers per 3-inch silicon wafer. In their animal experiments, they loaded a pain-relieving drug onto the grippers. The researchers’ studies found that the animals into which theragrippers were administered had higher concentrates of the pain reliever in their bloodstreams than did the control group. The drug stayed in the test subjects’ systems for nearly 12 hours versus two hours in the control group.
In addition to Gracias and Selaru, the journal article’s authors are Arijit Ghosh, Liyi Xu, Neha Gupta, Qianru Lin, Gayatri Pahapale, Wangqu Lu and Anjishnu Sarkar of the Johns Hopkins University Department of Chemical and Biomolecular Engineering; Ling Li and Venkata Akshintala of the Johns Hopkins University School of Medicine’s Division of Gastroenterology and Hepatology; Ranjeet Dash, Jenny Lam and Rana Rais of Johns Hopkins Drug Discovery and the Johns Hopkins University School of Medicine Department of Neurology.
The work was funded by the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health and the National Science Foundation. The Johns Hopkins University has filed patents on behalf of Gracias and Selaru related to this technology in accordance with the university’s conflict of interest policies.
Johns Hopkins Researchers Engineer Tiny, Shape-Changing Machines That Deliver Medicine Efficiently to the GI Tract
11/03/2020
“Theragrippers” are inspired by a parasitic worm that clamps onto its host’s intestines
When an open theragripper, left, is exposed to internal body temperatures, it closes on the intestinal wall. In the gripper’s center is a space for a small dose of a drug. Credit: Johns Hopkins University
Inspired by a parasitic worm that digs its sharp teeth into its host’s intestines, Johns Hopkins researchers have designed tiny, star-shaped microdevices that can latch onto intestinal mucosa and release drugs into the body.
David Gracias, Ph.D., a professor in the Johns Hopkins University Whiting School of Engineering, and Johns Hopkins gastroenterologist Florin M. Selaru, M.D., director of the Johns Hopkins Inflammatory Bowel Disease Center, led a team of researchers and biomedical engineers that designed and tested shape-changing microdevices that mimic the way the parasitic hookworm affixes itself to an organism’s intestines.
Made of metal and thin, shape-changing film and coated in a heat-sensitive paraffin wax, “theragrippers,” each roughly the size of a dust speck, potentially can carry any drug and release it gradually into the body.
A theragripper is about the size of a speck of dust. This swab contains dozens of the tiny devices. Credit: Johns Hopkins University.
The team published results of an animal study this week as the cover article in the journal Science Advances.
Gradual or extended release of a drug is a long-sought goal in medicine. Selaru explains that a problem with extended-release drugs is they often make their way entirely through the gastrointestinal tract before they’ve finished dispensing their medication.
“Normal constriction and relaxation of GI tract muscles make it impossible for extended-release drugs to stay in the intestine long enough for the patient to receive the full dose,” says Selaru, who has collaborated with Gracias for more than 10 years. “We’ve been working to solve this problem by designing these small drug carriers that can autonomously latch onto the intestinal mucosa and keep the drug load inside the GI tract for a desired duration of time.”
Thousands of theragrippers can be deployed in the GI tract. When the paraffin wax coating on the grippers reaches the temperature inside the body, the devices close autonomously and clamp onto the colonic wall. The closing action causes the tiny, six-pointed devices to dig into the mucosa and remain attached to the colon, where they are retained and release their medicine payloads gradually into the body. Eventually, the theragrippers lose their hold on the tissue and are cleared from the intestine via normal gastrointestinal muscular function.
Gracias notes advances in the field of biomedical engineering in recent years.
“We have seen the introduction of dynamic, microfabricated smart devices that can be controlled by electrical or chemical signals,” he says. “But these grippers are so small that batteries, antennas and other components will not fit on them.”
Theragrippers, says Gracias, don’t rely on electricity, wireless signals or external controls. “Instead, they operate like small, compressed springs with a temperature-triggered coating on the devices that releases the stored energy autonomously at body temperature.”
The Johns Hopkins researchers fabricated the devices with about 6,000 theragrippers per 3-inch silicon wafer. In their animal experiments, they loaded a pain-relieving drug onto the grippers. The researchers’ studies found that the animals into which theragrippers were administered had higher concentrates of the pain reliever in their bloodstreams than did the control group. The drug stayed in the test subjects’ systems for nearly 12 hours versus two hours in the control group.
In addition to Gracias and Selaru, the journal article’s authors are Arijit Ghosh, Liyi Xu, Neha Gupta, Qianru Lin, Gayatri Pahapale, Wangqu Lu and Anjishnu Sarkar of the Johns Hopkins University Department of Chemical and Biomolecular Engineering; Ling Li and Venkata Akshintala of the Johns Hopkins University School of Medicine’s Division of Gastroenterology and Hepatology; Ranjeet Dash, Jenny Lam and Rana Rais of Johns Hopkins Drug Discovery and the Johns Hopkins University School of Medicine Department of Neurology.
The work was funded by the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health and the National Science Foundation. The Johns Hopkins University has filed patents on behalf of Gracias and Selaru related to this technology in accordance with the university’s conflict of interest policies.
The technology is available for licensing through Johns Hopkins Technology Ventures.
Official link:https://www.hopkinsmedicine.org/new...-deliver-medicine-efficiently-to-the-gi-tract
Disclaimer:I wanna see how your Brilliant genius ass is gonna explain that.What is your clapback gonna be in regards to that.?Coming straight and direct from John Hopkins University Baltimore,Maryland
Its coming from directly John Hopkins University an accredited Ivy League post secondary education institution .I have already provided the link.here it is once again: https://www.hopkinsmedicine.org/new...-deliver-medicine-efficiently-to-the-gi-tract
Dum-Dum, nowhere on that page does it say anything about theragrippers being on COVID testing swabs.
Again:
Yo... this is unproductive bullshit.
Fuck you niggas for this. Yall worried about robotic nano tech and dont even know that organic nano tech is where science is shifting. It's looking more and more like DNA might actually work more like a set of transitors directing electron flow) than the true blueprints of what to build.
Get on my level.
Fuck you niggas for this. Yall worried about robotic nano tech and dont even know that organic nano tech is where science is shifting. It's looking more and more like DNA might actually work more like a set of transitors directing electron flow) than the true blueprints of what to build.
Get on my level.
Last edited:
Bruh do you want me to pull up the DARPA( Defense Advanced Research Projects Agency) Emergency Protocol Pre Covid19 Pandemic back around Febuary,March,2020.?
Where, you blockhead, immensely retarded muhfucka, is ANY reputable source proving that theragrippers are on COVID testing swabs? Post it.
STFU you premium white cracker...... you and your vaccine conspiracy bull.... million upon millions worldwide have been vaccinated.... and you continuously spread your shit about a few dozen dying.... more people die in car accidents..... you gonna stop people from driving cars fucktard? If I could only go back in time to the night that you were going to be conceived.... I'd kick your dads nads up into his throat.... save us from dealing with your idiot ass....
.
.
Not a problem at all.Just like the Covid19 Vaccine is under EUA(Emergency Use Authorization).Guess what my pal so was the Covid19 PCR Test(Nasal Swab,Forehead) and The Covid19 Antigen Test(fingerprick).Where have you been.?Its has already been approved by the FDA for Emergengy Use back during the height of the Pandemic.
DARPA has a 'game-changer' coronavirus test that's awaiting emergency approval, report says
This story has been updated to include comments made by Dr. Van Gieson to Fox News.March 19,2020
Though there is currently no known scientific cure for the disease known as COVID-19, researchers at the U.S.'s most advanced military agency has designed a coronavirus test that can identify people before they come infectious, according to a media report.
Described as a potential "game-changer," the test came from a project at the Defense Advanced Research Projects Agency (DARPA) that was initially designed for diagnosing those who have become poisoned by chemical warfare, The Guardian reports. It was repurposed for the coronavirus pandemic and may be able to detect the presence of the virus in as little as 24 hours after a person is infected.
“The concept fills a diagnostic gap worldwide,” the head of DARPA's biological technologies office, Dr. Brad Ringeisen, said in an interview with the news outlet. If approved by the FDA under its emergency use approval (EUA), Dr. Ringeisen said that the test could be “absolutely a gamechanger.”
IF YOU THINK YOU HAD CORONAVIRUS, NEW ANTIBODY TEST AVAILABLE WITHOUT TRIP TO DOCTOR'S OFFICE
The new form of testing looks at how a person's body responds during its fight with the coronavirus, as opposed to just looking for the presence of the virus itself.
"We think it would replace the current tests for the virus," Dr. Van Gieson told Fox News in reference to why it would be a "game-changer. "It tells you sooner and it tells you you've had it for a long time afterward."
Van Gieson added the test, which would require a milliliter of blood, provides "lasting value to the epidemiologists who want to evaluate the spread of the virus and how they were infected over time and geography."
The test "has the capability of providing a 6-month window to provide when someone was exposed," which could provide also important details to researchers about where someone was exposed, Van Gieson explained.
Fox News has reached out to the FDA with a request for comment for this story.
Van Gieson declined to give a specific timeframe for EUA approval, but added that DARPA's partners, which include Mt. Sinai, Princeton University and Duke University, have "generated very impressive data" so far.
The test, which is being done under DARPA's ECHO program, is not an antibody test, Van Gieson stressed. "It overcomes their shortcomings and it looks at specific changes to a host's RNA level and epigenetic level. Every time we experience something positive or negative, like an infection or starvation, there's a mark left on our genome. We're exploiting those marks."
If approved, the U.S. could carry out as many as 1 million tests a day, The Guardian reported. Currently, testing capacity in the U.S. is approximately 250,000 per day.
Last month, researchers from Harvard University said at least 5 million tests per day need to be delivered by early June "to deliver a safe social reopening," jumping to 20 million a day "to fully remobilize the economy" by late July.
DARPA was founded in 1958 by then-President Dwight Eisenhower as a response to the Russian launch of Sputnik I, the first man-made satellite launched into space.
The military agency is working on several fronts to overcome challenges related to COVID-19, including gene editing technologies via a new DARPA program known as Detect It with Gene Editing Technologies, or DIGET.
"With DIGET, it soon may be possible to not only confirm an influenza (or COVID-19) diagnosis, but also to determine the strain, the origin, and whether the strain is drug resistant," DARPA says on its website. "In addition, DIGET tools could assess the severity of disease to guide how the patient is triaged and treated."
DARPA has a 'game-changer' coronavirus test that's awaiting emergency approval, report says
Though there is currently no known scientific cure for the disease known as COVID-19, researchers at the U.S.'s most advanced military agency has designed a coronavirus test that can identify people before they come infectious, according to a media report.
and here is the official DARPA link from website back on March,19 2020 in regards to Covid19 testing:https://www.darpa.mil/work-with-us/covid-19
Last edited:
OMG this is the dumbest shit I have ever seen
There is a 24-page thread on the first page that begs to differ.
Lol
Bro...........Thats already history now it's in the past it can not be reversed nor can you hit the rewind button and go back. they have already approved the EUA for Covid19 testing back around Feb/March of 2020 during the height of the pandemic thats over now.The dynamics of the testing and how the procedures to administer it was already discussed and more than likely approved between John Hopkins University and DARPA.But none the less you cannot deny the protocols and procedures of the Covid19 Testing because John Hopkins University Medics have official links to the topic discussing the nature of the testing and the delivery of the medicines before the height of the pandemic .So once again the Covid19 testing is not (facts.factual) FDA approved but however it is EUA approved and according to John Hopkins University Medics if you have taken a Covid19 Test whether it be the Nasal Swab or the Covid19 Antigen test(fingerprick) you have already been defacto vaccinated according to them.You have been vaccinated long before Phizer,Johnson&Johnson,Moderna or Astrazeneca came out with intravenous vaccines.
Dr. Lorraine Day's Official Web Site documents her amazing recovery from cancer
Dr. Lorraine Day reversed her severe, advanced cancer by rebuilding her immune system by natural therapies, so her body could heal itself.
www.drday.com
“Drugs never cure disease; they only change the form and location of the disease.”
“osteoporosis is not caused by lack of calcium” “the more milk you drink, the more osteoporotic you become.”
“the entire foundation of conventional medicine is based on ERROR.”
Seems highly credible...
Bro.....................hold on a minute.I didnt say nothing was wrong with Nanotech.Nanotech is a brilliant and genius technology to have.It is one of best technologies that the human race has developed since the computer and the telephone real talk.A big Kudos to whomever came up with this.This is a marvel,genius and beautiful technology.This technology can single handly cure cancer no lie seriously.BTW nanotech already probably has the cure for cancer they just not gonna reveal to the public yet.Nanotech is responsible for the deaf to hear again,for the blind to see again,for those with heart problems to get going again and to bring back to life.Nanotech is responsible for a lot break through surgeries that doctors perform.Dont you ever put me in that realm of denying technology............Oh no,no, no..........I may deny science......But to deny technology is a whole different realm all together.The only pet peeve/beef i got with Nanotech is the people thats behind it.The evil and vile minds thats controlling it.thats it.Aint nothing wrong with nanotech.True talk
Last edited:
We live like dogs yet a university named after John Hopkins.
At one time third world countries starved to death while we threw away tons of food. When medicine was first studied, it was studied to improve a white male. Not the black race and especially not the black male. Unless we have already become a carbon copy of them (white devils).
At one time third world countries starved to death while we threw away tons of food. When medicine was first studied, it was studied to improve a white male. Not the black race and especially not the black male. Unless we have already become a carbon copy of them (white devils).
I did my research on him. He joined last summer and every post has been about Covid, except for him saying the world would be fucked up if Trump didn’t winSTFU you premium white cracker...... you and your vaccine conspiracy bull.... million upon millions worldwide have been vaccinated.... and you continuously spread your shit about a few dozen dying.... more people die in car accidents..... you gonna stop people from driving cars fucktard? If I could only go back in time to the night that you were going to be conceived.... I'd kick your dads nads up into his throat.... save us from dealing with your idiot ass....
.
.
I honestly can see why some so called coons do whatever they can to NOT be identified as black. We have some of the most dumb embarrassing people on the planet. I don’t understand how a human being can be so fucking stupid. Is this because of the crack problems of the 90’s?
Dr. Lorraine Day's Official Web Site documents her amazing recovery from cancer
Dr. Lorraine Day reversed her severe, advanced cancer by rebuilding her immune system by natural therapies, so her body could heal itself.www.drday.com
“Drugs never cure disease; they only change the form and location of the disease.”
“osteoporosis is not caused by lack of calcium” “the more milk you drink, the more osteoporotic you become.”
“the entire foundation of conventional medicine is based on ERROR.”
Seems highly credible...
Wait she cured herself from cancer???
Listen to that bitch!!!!
Oh well.
Similar threads
